Rapid clinical translation and registrational trials have led to US FDA approval of three BRAFi/MEKi combinations dabrafenib plus trametinib (melanoma, NSCLC, anaplastic thyroid cancer (ATC), and BRAF + solid tumors), vemurafenib plus cobimetinib (metastatic melanoma), and encorafenib plus binimetinib (approved in metastatic melanoma)4–7. Here, BRAF is linked to metastatic melanoma.